Centes­sa 2.0 with a twist: Medicxi com­bines six im­muno-derm star­tups with $100M

Eu­ro­pean biotech in­vestor Medicxi is bring­ing six star­tups un­der one roof to form an im­muno-der­ma­tol­ogy drug­mak­er with 14 pipeline projects in a move rem­i­nis­cent of its 10-in-1 Centes­sa Phar­ma­ceu­ti­cals un­veil­ing in 2021.

The health­care in­vest­ment firm will pump $100 mil­lion in fi­nanc­ing in­to the Boston and Gene­va-based biotech named Alys Phar­ma­ceu­ti­cals. It’s an amal­ga­ma­tion of Alde­na Ther­a­peu­tics, Graegis Phar­ma­ceu­ti­cals, Gran­u­lar Ther­a­peu­tics, Klir­na Biotech, Ni­ra Bio­sciences and Vimela Ther­a­peu­tics. Those make up the ma­jor­i­ty of the sev­en im­muno-derm star­tups Medicxi in­vest­ed in over the past few years, but the first, vi­tili­go drug­mak­er Vil­laris Ther­a­peu­tics, al­ready sold to In­cyte.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER